Castration-Resistant Prostate Cancer (CRPC) / Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Outlook 2026–2030
The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Size Increase Is Anticipated For The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Over The 2026–2030 Period?
The market size for castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics has demonstrated significant expansion in recent years. It is anticipated to increase from $8.43 billion in 2025 to $8.92 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.8%. This historical growth can be attributed to several factors, including the prevalence of prostate cancer, the emergence of hormone therapy resistance, continuous innovation in oncology drugs, the availability of hospital-based cancer care, and the rising aging male population.
The castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market size is projected to experience robust expansion over the coming years. This market is set to reach a valuation of $11.04 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.5%. Factors contributing to this anticipated growth during the forecast period include the rise of biomarker-driven treatment approaches, the development of advanced targeted therapies, increasing adoption of oral oncology drugs, expansion of the oncology drug pipeline, and a greater emphasis on personalized cancer care. Key trends expected during the same period encompass the growing utilization of androgen receptor inhibitors, the expansion of PARP inhibitor therapies, the broader application of combination treatment regimens, a heightened focus on precision oncology, and a general move towards oral oncology medications.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24495&type=smp
Which Economic Or Industry Drivers Are Impacting The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market?
The increasing occurrence of prostate cancer is anticipated to propel the future expansion of the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market. Prostate cancer is a type of malignancy that develops in the prostate gland, a small male gland situated beneath the bladder and in front of the rectum. This rising prevalence is attributed to the aging population, as the likelihood of developing prostate cancer substantially increases with age. Castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics are vital for treating prostate cancer by targeting advanced stages of the disease that no longer respond to conventional hormone therapy. These treatments enhance patient outcomes by slowing disease progression and managing symptoms, thereby improving the quality of life. For example, in October 2025, NHS Digital, a UK-based government agency responsible for healthcare data and statistics, reported 58,137 new diagnoses of prostate cancer in England in 2023, which signifies a 6 percent increase compared with 2022. Hence, the growing prevalence of prostate cancer is actively driving the growth of the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market.
How Is The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Segmented Across Key Categories?
The castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market covered in this report is segmented –
1) By Therapy Type: Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy
2) By Route Of Administration: Oral, Injectable, Intravenous
3) By End User: Hospitals, Oncology Centers, Ambulatory Surgical Centers, Other End Users
Subsegments:
1) By Hormonal Therapy: Androgen Receptor (AR) Inhibitors, Androgen Synthesis Inhibitors, Luteinizing Hormone-Releasing Hormone (LHRH) Agonists Or Antagonists, Gonadotropin-Releasing Hormone (GnRH) Agonists Or Antagonists
2) By Chemotherapy: Taxanes, Platinum-Based Agents, Other Chemotherapies
3) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines
4) By Targeted Therapy: Poly ADP-Ribose Polymerase (PARP) Inhibitors, Phosphoinositide 3-Kinase (PI3K) Or Protein Kinase B (PI3K) Or Mammalian Target Of Rapamycin (mTOR) Inhibitors, Tyrosine Kinase Inhibitors (TKIs), Deoxyribonucleic Acid Damage Response (DDR) Inhibitors
5) By Radiation Therapy: External Beam Radiation Therapy, Brachytherapy, Radiopharmaceuticals
Which Upcoming Trends Are Expected To Influence The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market?
Leading companies operating within the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market are prioritizing the creation of novel products and obtaining necessary approvals, particularly for innovations like dual-action tablets, aimed at boosting treatment effectiveness and improving patient results. Dual-action tablets represent sophisticated formulations that integrate two therapeutic agents into a single dosage, allowing for the simultaneous targeting of multiple pathways crucial in castration-resistant prostate cancer (CRPC) treatment. A notable illustration occurred in August 2023, when Janssen Pharmaceuticals, a pharmaceutical company based in Belgium, secured approval from the U.S. Food and Drug Administration (FDA) for Akeega. This novel tablet is designed for treating adults diagnosed with BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC). Akeega functions as a precision medicine, bringing together a PARP inhibitor (niraparib) and a CYP17 inhibitor (abiraterone acetate), specifically tailored for patients carrying BRCA mutations. When administered alongside prednisone, it substantially improves radiographic progression-free survival (rPFS) when compared to conventional hormonal therapy on its own.
Who Are The Dominant Players Shaping The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Landscape?
Major companies operating in the castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market are Pfizer Inc., Johnson And Johnson, Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Daiichi Sankyo Co. Ltd., Lantheus Holdings Inc., POINT Biopharma Global Inc., Clovis Oncology Inc., Arvinas Inc., Clarity Pharmaceuticals Ltd, Modra Pharmaceuticals B.V., Oncternal Therapeutics Inc., Zenith Epigenetics Ltd., ESSA Pharma Inc.
Read the full castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market report here:
What Are The Top-Performing Regions Within The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market?
North America was the largest region in the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=24495&type=smp
Browse Through More Reports Similar to the Global Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market 2026, By The Business Research Company
Prostate Cancer Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/prostate-cancer-drugs-global-market-report
Urothelial Carcinoma Treatment Market Report 2026
Prostate Cancer Nuclear Medicine Diagnostics Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.
